title: Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11.
abstract: A phase II trial was conducted in subjects with human papillomavirus (HPV) associated high-grade cervical dysplasia testing the safety and efficacy of a microparticle encapsulated pDNA vaccine. Amolimogene expresses T cell epitopes from E6 and E7 proteins of HPV types 16 and 18. An analysis was performed on a subset of HLA-A2+ subjects to test whether CD8+ T cells specific to HPV 16, 18, 6 and 11 were increased in response to amolimogene immunization. Of the 21 subjects receiving amolimogene, 11 had elevated CD8+ T cell responses to HPV 16 and/or 18 peptides and seven of these also had increases to corresponding HPV 6 and/or 11 peptides. In addition, T cells primed and expanded in vitro with an HPV 18 peptide demonstrated cross-reactivity to the corresponding HPV 11 peptide. These data demonstrate that treatment with amolimogene elicits T cell responses to HPV 16, 18, 6 and 11.
authors.affiliation: Eisai Inc., Andover, MA 01810, USA. mark_matijevic@eisai.com
authors.forename: Mark
authors.initials: M
authors.lastname: Matijevic
authors.forename: Mary Lynne
authors.initials: ML
authors.lastname: Hedley
authors.forename: Robert G
authors.initials: RG
authors.lastname: Urban
authors.forename: Roman M
authors.initials: RM
authors.lastname: Chicz
authors.forename: Christa
authors.initials: C
authors.lastname: Lajoie
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Luby
mesh_terms: D000328:Adult; D017951:Antigen Presentation; D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology*; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D004311:Double-Blind Method; D005260:Female; D052140:Human papillomavirus 11 / Q000276:immunology; D052162:Human papillomavirus 16 / Q000276:immunology*; D052161:Human papillomavirus 18 / Q000276:immunology*; D052163:Human papillomavirus 6 / Q000276:immunology; D006801:Humans; D007114:Immunization; D016056:Immunodominant Epitopes; D010957:Plasmids; D011098:Polyglactin 910; D054504:Precursor Cells, T-Lymphoid / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000628:therapy* / Q000821:virology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*; D055815:Young Adult; D002578:Uterine Cervical Dysplasia / Q000276:immunology* / Q000628:therapy* / Q000821:virology
chemical_list: D000956:Antigens, Viral; D019496:Cancer Vaccines; D016056:Immunodominant Epitopes; D019444:Vaccines, DNA; C534802:amolimogene bepiplasmid; D011098:Polyglactin 910